These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36051360)

  • 1. No Evidence that
    Castaño-Bonilla T; Barragán E; Sargas C; Sanz A; Algarra L; Herrera-Puente P; García-Boyero R; Barrios M; Martinez-Cuadron D; Rodriguez-Veiga R; Boluda B; Gil C; Serrano-López J; Martínez-López J; Sayas-Lloris MJ; Olave MT; Riaza-Grau R; Castillo TB; Larrayoz MJ; Amigo R; Jiménez-Velasco A; Sánchez J; Ayala R; Blas C; Lainez D; Serrano-López J; Sanz MA; Alonso-Domínguez JM; Montesinos P
    Dis Markers; 2022; 2022():3132941. PubMed ID: 36051360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
    Mortland L; Alonzo TA; Walter RB; Gerbing RB; Mitra AK; Pollard JA; Loken MR; Hirsch B; Raimondi S; Franklin J; Pounds S; Cao X; Rubnitz JE; Ribeiro RC; Gamis A; Meshinchi S; Lamba JK
    Clin Cancer Res; 2013 Mar; 19(6):1620-7. PubMed ID: 23444229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemtuzumab ozogamicin in acute myeloid leukemia.
    Godwin CD; Gale RP; Walter RB
    Leukemia; 2017 Sep; 31(9):1855-1868. PubMed ID: 28607471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.
    Oya S; Ozawa H; Morishige S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Nakamura T; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
    Int J Hematol; 2024 Sep; 120(3):297-304. PubMed ID: 38963637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with
    Teich K; Krzykalla J; Kapp-Schwoerer S; Gaidzik VI; Schlenk RF; Paschka P; Weber D; Fiedler W; Kühn MWM; Schroeder T; Mayer K; Lübbert M; Ramachandran D; Benner A; Ganser A; Döhner H; Heuser M; Döhner K; Thol F
    Haematologica; 2021 Nov; 106(11):2986-2989. PubMed ID: 34047179
    [No Abstract]   [Full Text] [Related]  

  • 8. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.
    Gbadamosi M; Meshinchi S; Lamba JK
    Future Oncol; 2018 Dec; 14(30):3199-3213. PubMed ID: 30039981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
    Oya S; Ozawa H; Nakamura T; Mori A; Ochi S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
    Int J Hematol; 2024 Aug; 120(2):194-202. PubMed ID: 38853211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
    Rafiee R; Chauhan L; Alonzo TA; Wang YC; Elmasry A; Loken MR; Pollard J; Aplenc R; Raimondi S; Hirsch BA; Bernstein ID; Gamis AS; Meshinchi S; Lamba JK
    Blood Cancer J; 2019 May; 9(6):51. PubMed ID: 31113932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.
    Takeshita A
    Int J Hematol; 2013 Jun; 97(6):703-16. PubMed ID: 23709007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
    Baron J; Wang ES
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.
    Gale RE; Popa T; Wright M; Khan N; Freeman SD; Burnett AK; Russell NH; Hills RK; Linch DC
    Blood; 2018 Jan; 131(4):468-471. PubMed ID: 29229596
    [No Abstract]   [Full Text] [Related]  

  • 15. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin.
    Fernandez HF; Sun Z; Litzow MR; Luger SM; Paietta EM; Racevskis J; Dewald G; Ketterling RP; Rowe JM; Lazarus HM; Tallman MS
    Blood; 2011 May; 117(20):5306-13. PubMed ID: 21415269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
    Tarlock K; Alonzo TA; Gerbing RB; Raimondi SC; Hirsch BA; Sung L; Pollard JA; Aplenc R; Loken MR; Gamis AS; Meshinchi S
    Clin Cancer Res; 2016 Apr; 22(8):1951-7. PubMed ID: 26644412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.
    Khan N; Hills RK; Virgo P; Couzens S; Clark N; Gilkes A; Richardson P; Knapper S; Grimwade D; Russell NH; Burnett AK; Freeman SD
    Leukemia; 2017 May; 31(5):1059-1068. PubMed ID: 27795558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab ozogamicin for acute myeloid leukemia.
    Appelbaum FR; Bernstein ID
    Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
    Gbadamosi MO; Shastri VM; Elsayed AH; Ries R; Olabige O; Nguyen NHK; De Jesus A; Wang YC; Dang A; Hirsch BA; Alonzo TA; Gamis A; Meshinchi S; Lamba JK
    Leukemia; 2022 Aug; 36(8):2022-2031. PubMed ID: 35688939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
    Cowan AJ; Laszlo GS; Estey EH; Walter RB
    Front Biosci (Landmark Ed); 2013 Jun; 18(4):1311-34. PubMed ID: 23747885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.